HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

Abstract
TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In the present study of a large cohort of DLBCL patients treated with rituximab plus CHOP (R-CHOP), we show that those with TP53 mutations had worse overall and progression-free survival compared with those without. Unlike earlier studies of patients treated with CHOP, TP53 mutation has predictive value for R-CHOP-treated patients with either the germinal center B-cell or activated B-cell DLBCL subtypes. Furthermore, we identified the loop-sheet-helix and L3 motifs in the DNA-binding domain to be the most critical structures for maintaining p53 function. In contrast, TP53 deletion and loss of heterozygosity did not confer worse survival. If gene mutation data are not available, immunohistochemical analysis showing > 50% cells expressing p53 protein is a useful surrogate and was able to stratify patients with significantly different prognoses. We conclude that assessment of TP53 mutation status is important for stratifying R-CHOP-treated patients into distinct prognostic subsets and has significant value in the design of future therapeutic strategies.
AuthorsZijun Y Xu-Monette, Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L Richards, Eric D Hsi, X Frank Zhao, William W L Choi, Xiaoying Zhao, J Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Ai, Maurilio Ponzoni, Andrés J M Ferreri, Fan Zhou, Brad S Kahl, Jane N Winter, Wei Xu, Jianyong Li, Ronald S Go, Yong Li, Miguel A Piris, Michael B Møller, Roberto N Miranda, Lynne V Abruzzo, L Jeffrey Medeiros, Ken H Young
JournalBlood (Blood) Vol. 120 Issue 19 Pg. 3986-96 (Nov 08 2012) ISSN: 1528-0020 [Electronic] United States
PMID22955915 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Tumor Suppressor Protein p53
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adult
  • Aged
  • Alleles
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cohort Studies
  • Computational Biology
  • Cyclophosphamide (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Exons
  • Female
  • Gene Deletion
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Loss of Heterozygosity
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, genetics, mortality)
  • Male
  • Middle Aged
  • Mutation
  • Mutation Rate
  • Mutation, Missense
  • Neoplasm Staging
  • Prednisone (therapeutic use)
  • Prognosis
  • Rituximab
  • Treatment Outcome
  • Tumor Suppressor Protein p53 (genetics, metabolism)
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: